NICE's lingering OS doubt scuppers Ninlaro

5 September 2017

Missing data to prove that a combination involving Ninlaro (ixazomib) prolongs overall survival in relapsed or refractory (R/R) multiple myeloma (MM) compared with the current treatment has added further delay to National Health Service (NHS) funding for patients in England and Wales.

Japanese pharma major Takeda (TYO: 4502) has expressed frustration at the decision of the National Institute for Health and Care Excellence (NICE) to issue a second negative appraisal consultation document (ACD) for ixazomib in combination with lenalidomide and dexamethasone (IRd), for the treatment of patients who have received one or more previous therapies.

"CDF is supposed to provide access to innovative cancer drugs while further clinical evidence is gathered and used to demonstrate that these drugs are cost-effective – Takeda is collecting this data for ixazomib"

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK